KYORIN Pharmaceutical Co., Ltd.
Stock Price Chart
2026/08/21 UpdatedPrice Trend
2026/08/21 UpdatedPrice & Trading Details
2026/08/21 UpdatedPRICE
TRADING
Analyst Recommendations 1 analysts
Updated 2026/08/01Earnings Calendar
Updated 2026/08/01Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2015/05/12 | ¥28.10 | ¥33.53 | +19.3% |
| 2015/02/01 | ¥79.00 | ¥81.32 | +2.9% |
| 2014/05/08 | ¥37.50 | ¥36.84 | -1.8% |
| 2014/02/03 | ¥65.60 | ¥65.26 | -0.5% |
Shareholder Composition
Updated 2026/08/01Major Holders
Updated 2026/08/01| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
ADVISORS' INNER CIRCLE FUND II-KOPERNIK GLOBAL ALL-CAP FUND
|
2.1M | +8.21% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
582.3K | 0.00% | |
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
569.8K | 0.00% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
383.6K | 0.00% | |
|
Dimensional ETF Trust-Dimensional International Small Cap Value ETF
|
215.7K | +4.25% | |
|
DFA INVESTMENT DIMENSIONS GROUP INC-DFA Intl Small Cap Value PORT.
|
190.1K | 0.00% |
Dividend History
Updated 2026/08/23| Year | Dividend | Change |
|---|---|---|
| 2026 | ¥37 | -35.1% |
| 2025 | ¥57 | +9.6% |
| 2024 | ¥52 | 0.0% |
| 2023 | ¥52 | 0.0% |
| 2022 | ¥52 | - |
Financial Performance
2026/08/23 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥113,270M | ¥119,532M | ¥130,087M | ¥126,257M |
| Gross Profit | ¥50,167M | ¥51,628M | ¥59,535M | ¥51,622M |
| Operating Income | ¥5,124M | ¥6,234M | ¥12,568M | ¥3,567M |
| Pretax Income | ¥6,972M | ¥7,305M | ¥12,943M | ¥4,705M |
| Net Income | ¥4,723M | ¥5,475M | ¥9,086M | ¥3,448M |
| EPS | ¥82.44 | ¥92.74 | ¥158.17 | - |
| Operating Margin | 4.52% | 5.22% | 9.66% | 2.83% |
| Balance Sheet | ||||
| Total Assets | ¥176,045M | ¥177,627M | ¥193,618M | ¥195,455M |
| Total Equity | ¥125,460M | ¥130,733M | ¥136,284M | ¥142,425M |
| Total Liabilities | ¥50,585M | ¥46,894M | ¥57,334M | ¥53,030M |
| Cash | ¥19,394M | ¥13,886M | ¥15,021M | ¥11,802M |
| Interest-bearing Debt | ¥21,277M | ¥20,946M | ¥28,439M | ¥23,785M |
| Equity Ratio | 71.27% | 73.60% | 70.39% | 72.87% |
| D/E Ratio | 0.17 | 0.16 | 0.21 | 0.17 |
| Cash Flow | ||||
| Operating CF | ¥2,008M | ¥1,549M | ¥3,506M | ¥6,381M |
| Investing CF | -¥6,275M | -¥3,187M | -¥6,323M | -¥1,644M |
| Financing CF | -¥3,363M | -¥3,347M | ¥3,952M | -¥7,956M |
| Free CF | -¥7,397M | -¥4,697M | -¥2,787M | ¥2,405M |
| Efficiency | ||||
| ROE | 3.76% | 4.19% | 6.67% | 2.42% |
| ROA | 2.68% | 3.08% | 4.69% | 1.76% |
Latest IR Information
-
Promotion activities for the allergy conjunctivitis treatment 'Allegion® Eyelid Cream 0.5%'
Joint promotional activities for Allegion® Eyelid Cream 0.5% in the Japanese market with Santen. The target area is medical institutions other than ophthalmology. If disclosure reasons arise affecting the consolidated earnings forecast for the fiscal year ending March 2027, notification...
Read more -
Q1 Earnings Report (Consolidated) for Fiscal Year Ending March 2027
In the first quarter of fiscal year ending March 2027, Kyorin Pharmaceutical reported net sales of approximately ¥296.5 billion, operating income of approximately ¥96.4 billion, and net income of approximately ¥82.4 billion, achieving increases compared to the same period last...
Read more -
Q1 FY2027 Financial Results Supplementary Materials
The company's sales for the first quarter of FY2027 were ¥29.7 billion, a decrease of ¥5.75 hundred million YoY; operating profit was ¥1.0 billion, down ¥1.4 hundred million; net profit was ¥824 million, a 60.8% decline. Sales were affected by...
Read more -
Joint Sales Promotion Agreement for Allegion® Eyelid Cream Signed ｜ July 2026
Kyorin Pharmaceutical has signed a joint sales promotion agreement with Santen Pharmaceutical for Allegion® Eyelid Cream in Japan, planning to commence promotion to non-ophthalmic medical institutions from August 2026. The initiative aims to expand business and improve patient QOL.
Read more -
Financial Summary for the Fiscal Year Ending March 2026 [Japanese Standards] (Consolidated)
For the fiscal year ending March 2026, consolidated net sales were ¥126.257 billion (a decrease of 2.9% YoY), operating income was ¥3.567 billion (down 71.6% YoY), and net income attributable to owners of the parent was ¥3.448 billion (down 62.0%...
Read more
Latest News (5 items)
-
Average Analyst Rating: none
Average Target Price: ¥1,100
Rating Score: 4.00 (Based on 1 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
KYORIN Pharmaceutical Co., Ltd., through its subsidiaries, researches and develops, manufactures, and sells generic drugs in Japan and internationally. The company is also involved in drug discovery and licensing activities. It also offers infectious disease-related products; over-the-counter drug; and generic drugs. The company was formerly known as KYORIN Holdings, Inc. KYORIN Pharmaceutical Co., Ltd. was founded in 1923 and is headquartered in Tokyo, Japan.
